Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 2, 2011, Pages 372-377

  Huang, Chao H ^a,c   Williamson, Stephen K ^a   Van Veldhuizen, Peter J ^a,c   Hsueh, Chung Tsen ^d   Allen, Ace ^a   Tawfik, Ossama ^a   Wick, Jo ^a   Smith, Holly ^b   Uypeckcuat, Adelina M ^c   Mayo, Matthew ^a   Kelly, Karen ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d LOMA LINDA UNIVERSITY   (United States)

Author keywords

Docetaxel; Imatinib; Platelet derived growth factor receptor; Recurrent Lung cancer

Indexed keywords

DEXAMETHASONE; DOCETAXEL; ERLOTINIB; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COUGHING; DRUG DOSE REDUCTION; DYSPNEA; FEMALE; HEART INFARCTION; HUMAN; HYPOKALEMIA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SYNCOPE; THORAX PAIN; TREATMENT RESPONSE; VOMITING;

EID: 79551570654     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318200f9ad     Document Type: Article

References (27)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98.
2. Shepherd FA, Danncey J, Ramlau R, et al. Prospective randomized trial of docetaxel vs. best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
3. Fossella FV, DeVore R, Kerr RN, et al. and the TAX Non-Small-Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-smallcell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
4. Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007;14:285-294.
5. Wang D, Huang HJ, Kazlauskas A, et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999;59:1464-1472.
6. Hellstrom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Exp Cell Res 1999;186:264-272.
7. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15:197-204.
8. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of plateletderived growth factor and its receptors. Lab Invest 1997;77:431-436.
9. Fitzer-Attas C, Feldman M, Eisenbach L. Expression of functionally intact PDGF-alpha receptors in highly metastatic 3LL Lewis lung carcinoma cells. Int J Cancer 1993;21:315-322.
10. Antoniades HN, Galanopoulos T, Neville-Golden J, et al. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci USA 1992;89:3942-3946.
11. Donnem T, Al-Saad S, Al-Shibli K, et al. Prognostic impact of plateletderived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 2008;3:963-970.
12. McDermott U, Ames RY, Iafrate AJ, et al. Ligand-dependent plateletderived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 2009;9:3937-3946.
13. Bauman JE, Eaton KD, Martins RG, et al. Antagonism of plateletderived growth factor receptor in non-small cell lung cancer: rationale and investigations. Clin Cancer Res 2007;13:4632-4636s.
14. Zhang P, Gao WY, Turner S, et al. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2003;2:1.
15. Pietras K, Rubin K, Sjöblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-5484.
16. Uehara H, Kim SJ, Karashima T, et al. Effects of blocking plateletderived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:458-470.
17. Mathew P, Thall PF, Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004;22:3323-3329.
18. Rogatko A, Litwin S. Phase II studies: which is worse, false positive or false negative? J Natl Cancer Inst 1996;88:462.
19. White LA, Schmidt AM, Sjak-Shie NN, et al. A phase II study of docetaxel (D) plus Imatinib (I) in patients with previously treated non-small cell lung cancer. J Clin Oncol 2007;18 S: abst 18200.
20. Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced platinumresistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008;113:665-667.
21. Waterhouse DM, Mainwaring M, Barton J, et al. Phase II pilot results of Imatinib mesylate with weekly docetaxel in metastatic breast cancer. J Clin Oncol 2008;15 S: abst 1090.
22. Haley BB, Ashfaq R, DeHaas M, et al. A phase I/II study of Imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer. J Clin Oncol 2007;18 S: abst 11039.
23. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanism. FASEB J 2004;18:338-340.
24. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007;177:489-500.
25. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-4280.
26. Browder T, Butterfield CE, Kräling BM, et al. Angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.
27. Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25:1377-1382.